• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2: Buyer Beware in the Diagnostic Test Market

Article

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a "buyer beware" market, according to Daniel F. Hayes, MD.

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a “buyer beware” market, according to Daniel F. Hayes, MD.

Since the FDA does not require clinical utility for clearance or approval, which has resulted in a market with a number of FDA-approved tests that may not be worth much in terms of taking care of patients. In contrast, there are laboratory-developed tests that are quite good, but haven’t been approved, Dr Hayes explained.

“Right now it’s really a mess and many of us believe that it needs to be clarified,” he said.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.